Biocon Biologics on Monday said it has inked an out-licensing agreement with Yoshindo Inc to commercialise its two biosimilar assets in the Japanese market.
Under the terms of this deal, Japan-based Yoshindo gets exclusive commercialisation rights in Japan for Ustekinumab and Denosumab — developed and manufactured by Biocon Biologics — for an addressable market opportunity of USD 700 million, Biocon Biologics said in a statement.
Biocon Biologics, a unit of Biocon, will rec ..
Ustekinumab biosimilar is a monoclonal antibody used to treat several autoimmune conditions, including psoriasis, Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis.
Denosumab is a monoclonal antibody for the treatment of osteoporosis.
“Once approved, these products will expand our offering of affordable, high-quality biosimilars in the Japanese market and help address unmet patient needs in bone health and immunology therapy areas,” Biocon Biologic ..